IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04925713|
Recruitment Status : Completed
First Posted : June 14, 2021
Last Update Posted : February 8, 2023
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cutaneous Squamous Cell Carcinoma Basal Cell Carcinoma||Biological: IFx-Hu2.0||Phase 1|
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
This is a multi-site, open-label, interventional, prospective, phase 1 trial to assess safety and tolerability of IFx-Hu2.0 in patients with basal cell carcinoma, squamous cell carcinoma, or cutaneous melanoma.
A total of approximately one hundred (100) male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with at least one cutaneous melanoma, squamous cell carcinoma, or basal cell carcinoma lesion accessible for direct injection, who meet all inclusion and no exclusion criteria, will be eligible for enrollment and treatment with IFx-Hu2.0.
Enrollees will receive IFx-Hu2.0 as a single intralesional injection at a single time point. The target dose will be 100 μg of plasmid DNA per lesion injected at a final dose volume of 200 μL per lesion. The injected lesion will be completely excised at the follow-up visit four weeks later and will be biopsied for confirmation of diagnosis and for the establishment of a pathological response baseline peripheral blood will be collected from these patients prior to treatment administration and at the follow-up visit four weeks later. These samples will be used to perform complete blood counts (CBC) and clinical chemistry tests. A urine sample will be obtained for urinalysis for protein and blood at the same frequency. Blood samples will be drawn for immune response evaluation as well.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Trial of IFx-Hu2.0 to Evaluate Safety in Patients With Skin Cancer|
|Actual Study Start Date :||June 10, 2021|
|Actual Primary Completion Date :||October 7, 2021|
|Actual Study Completion Date :||March 10, 2022|
Experimental: IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion
One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.
Route of Administration:
Mechanism of Action:
Other Name: pAc/emm55
- Rate of Adverse Events [ Time Frame: 28 days post injection ]Rate of Adverse Events reported per Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- Number of Patients who completed the trial [ Time Frame: 28 days post injection ]Number of Patients who completed the trial per protocol without major deviations
- Rate of Pathological Complete Response (pCR) [ Time Frame: Definitive surgery 4 weeks post treatment ]Rate of patients with complete absence of residual viable tumor in the treated tumor bed on histological assessment of fully excised lesion
- Rate of Major Pathological Response (mPR) [ Time Frame: Definitive surgery 4 weeks post treatment ]Rate of patients with ≤10% of residual viable tumor present in the treated tumor bed on histological assessment of fully excised lesion
- Rate of Partial Pathological Response (pPR) [ Time Frame: Definitive surgery 4 weeks post treatment ]Rate of patients with ≤50% of residual viable tumor present in the treated tumor bed on histological assessment of fully excised lesion
- Rate of Pathological Non-Response (pNR) [ Time Frame: Definitive surgery 4 weeks post treatment ]Rate of patients with >50% of residual viable tumor present in the treated tumor bed on histological assessment of fully excised lesion
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Ability to receive intralesional injections
- Male or female, aged ≥ 18 years
- Histologically confirmed cutaneous squamous cell carcinoma, or basal cell carcinoma with accessible lesions (based on archival tissue or new tissue biopsy for histological confirmation)
- Life expectancy of at least 24 weeks at the time of screening
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Must have measurable disease greater than 3 mm
- At least one injectable lesion
Adequate organ function as defined below (Note: these screening laboratory tests must be obtained within two weeks prior to the baseline visit, Day 0):
10.1. Hemoglobin (Hb) >10 g/dL 10.2. Absolute Neutrophil Count (ANC) >1,500 cells/mcL 10.3. Platelet Count (PLT) >75,000/mcL 10.4. Prothrombin Time (PT) or International Normalized Ratio (INR) ≤1.5 times the institutional ULN unless patient is receiving anticoagulant therapy as long as PT or INR is within therapeutic range of the intended use of anticoagulants.
10.5. Activated Partial Thromboplastin Time (aPTT) ≤1.5 times the institutional ULN unless patient is receiving anticoagulant therapy as long as aPTT is within therapeutic range of the intended use of anticoagulants.
10.6. Serum Creatinine (SCr) ≤1.5 times the institutional ULN 10.7. Total Bilirubin ≤1.5 times the institutional ULN 10.8. Aspartate Aminotransferase (AST) ≤3 times the institutional ULN 10.9. Alanine Aminotransferase (ALT) ≤3 times the institutional ULN 10.10. Lactate Dehydrogenase (LDH) ≤2 times the institutional ULN 10.11. Alkaline Phosphatase (ALP) ≤2.5 times the institutional ULN 10.12. Gamma GT (GGT) ≤2.5 times the institutional ULN
- Lymphocyte count ≥500,000 cells/mL
- For females of reproductive potential: must have a negative urine or serum pregnancy test result within 24 hours prior to receiving IFx-Hu2.0; must use highly effective contraception (e.g.,licensed hormonal or barrier methods) for at least one month prior to screening and agreement to use such a method during study participation and for an additional 26 weeks after the end of study treatment
- For males of reproductive potential: use of barrier method or other methods to ensure effective contraception with partner
- Concurrent participation in any other clinical trial
- Inability to consent for self
- Lesions on scalp with bone erosions must not be selected as injection sites for IFx-Hu2.0
- Life expectancy of fewer than 24 weeks at the time of screening
- Prior systemic anti-cancer treatment within three weeks from start of treatment (Day 0)
- Treatment with any investigational product within the three weeks preceding injection
- Concurrent chemotherapy or biological therapy. Concurrent radiotherapy is allowed as long as it is not the same site as the injected lesion.
- Current treatment with systemic immunosuppressive corticosteroid (greater than 10 mg of daily prednisone) doses or other immunosuppressants such as those needed for solid organ transplants. Medications needed to treat conditions such as reactive airway disease are not excluded.
- Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 26 weeks after the last dose of trial treatment
- Immunizations for encapsulated bacteria were not given for patients who have undergone a splenectomy
- Serious underlying medical or psychiatric conditions, active infections requiring the use of antimicrobial drugs, or active bleeding that would make the subject unsuitable or unable to participate in the study
- Active Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) or Hepatitis B/C. Patients with treated HIV/AIDS or Hepatitis B/C with no evidence of active infection may be enrolled
- History of organ allograft transplantation
- Presence of any uncontrolled and significant medical or psychiatric condition which would interfere with trial safety assessments
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04925713
|United States, Florida|
|Moore Clinical Research|
|Brandon, Florida, United States, 33716|
|Responsible Party:||Morphogenesis, Inc.|
|Other Study ID Numbers:||
|First Posted:||June 14, 2021 Key Record Dates|
|Last Update Posted:||February 8, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms by Site